Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib.
Hepatocellular carcinoma
lenvatinib
overall survival
proteinuria
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
25
01
2021
revised:
06
02
2021
accepted:
12
02
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
Lenvatinib, a multitargeted tyrosine kinase inhibitor, was recently approved for hepatocellular carcinoma (HCC) treatment in Japan; however, the association between proteinuria following lenvatinib administration in HCC patients and early mortality is unknown. This study aimed to examine the association between nephrotic-range proteinuria (NRP) and mortality and evaluated the risk factors for NRP among Japanese HCC patients treated with lenvatinib. We retrospectively analyzed 45 consecutive patients receiving lenvatinib from 2018-2019. Primary outcome was overall survival. Cox proportional hazards regression was used to evaluate the association between NRP and overall survival. Logistic regression analyses were used to identify NRP risk factors after lenvatinib initiation. The median age was 66 years, 56% were women, and 20% had pre-existing proteinuria. During a 1-year median follow-up, 24 died, and 5 developed NRP. Univariable logistic regression showed that pre-existing proteinuria was associated with higher NRP risk; however, the association was not significant after covariate adjustment. Following multivariable Cox analysis, NRP did not affect overall survival in advanced HCC patients receiving lenvatinib. Urinalysis findings should be monitored regularly in patients receiving lenvatinib because NRP incidence was comparable to that of prior studies. Identifying the predictors of NRP after lenvatinib initiation warrants further investigation.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Lenvatinib, a multitargeted tyrosine kinase inhibitor, was recently approved for hepatocellular carcinoma (HCC) treatment in Japan; however, the association between proteinuria following lenvatinib administration in HCC patients and early mortality is unknown. This study aimed to examine the association between nephrotic-range proteinuria (NRP) and mortality and evaluated the risk factors for NRP among Japanese HCC patients treated with lenvatinib.
PATIENTS AND METHODS
METHODS
We retrospectively analyzed 45 consecutive patients receiving lenvatinib from 2018-2019. Primary outcome was overall survival. Cox proportional hazards regression was used to evaluate the association between NRP and overall survival. Logistic regression analyses were used to identify NRP risk factors after lenvatinib initiation.
RESULTS
RESULTS
The median age was 66 years, 56% were women, and 20% had pre-existing proteinuria. During a 1-year median follow-up, 24 died, and 5 developed NRP. Univariable logistic regression showed that pre-existing proteinuria was associated with higher NRP risk; however, the association was not significant after covariate adjustment. Following multivariable Cox analysis, NRP did not affect overall survival in advanced HCC patients receiving lenvatinib.
CONCLUSION
CONCLUSIONS
Urinalysis findings should be monitored regularly in patients receiving lenvatinib because NRP incidence was comparable to that of prior studies. Identifying the predictors of NRP after lenvatinib initiation warrants further investigation.
Identifiants
pubmed: 33910848
pii: 35/3/1647
doi: 10.21873/invivo.12423
pmc: PMC8193319
doi:
Substances chimiques
Antineoplastic Agents
0
Phenylurea Compounds
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1647-1653Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Kidney Int. 2014 Feb;85(2):457-70
pubmed: 24067439
Diabetes Care. 2014 Jan;37 Suppl 1:S5-13
pubmed: 24357214
Drugs Real World Outcomes. 2020 Jun;7(2):141-149
pubmed: 32048238
N Engl J Med. 2008 Mar 13;358(11):1129-36
pubmed: 18337603
J Nephrol. 2017 Apr;30(2):171-180
pubmed: 27154025
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76
pubmed: 16172168
Korean J Intern Med. 2014 Jan;29(1):40-8
pubmed: 24574832
Br J Cancer. 2016 Jun 14;114(12):1313-7
pubmed: 27228299
Endocrine. 2017 Apr;56(1):121-128
pubmed: 28155175
Hepatol Commun. 2020 Jun 20;4(8):1218-1228
pubmed: 32766480
Hepatol Res. 2019 Jan;49(1):111-117
pubmed: 30144256
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Kidney Int. 2006 Jun;69(11):1986-95
pubmed: 16641924
Expert Rev Clin Pharmacol. 2020 Mar;13(3):311-320
pubmed: 32105149
Int J Cancer. 2008 Feb 1;122(3):664-71
pubmed: 17943726
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
World J Gastroenterol. 2020 Aug 14;26(30):4465-4478
pubmed: 32874058
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088